

Supplemental online content for:

Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study

Quisette P. Janssen, MD; Jacob L. van Dam, MD; Laura R. Prakash, MD; Deesje Doppenberg, MD; Christopher H. Crane, MD; Casper H.J. van Eijck, MD, PhD; Susannah G. Ellsworth, MD; William R. Jarnagin, MD; Eileen M. O'Reilly, MD; Alessandro Paniccia, MD; Marsha Reyngold, MD, PhD; Marc G. Besselink, MD, PhD; Matthew H.G. Katz, MD; Ching-Wei D. Tzeng, MD; Amer H. Zureikat, MD; Bas Groot Koerkamp, MD, PhD; and Alice C. Wei, MD; for the Trans-Atlantic Pancreatic Surgery (TAPS) Consortium

J Natl Compr Canc Netw 2022;20(7):783–791.e1

eTable 1: Radiotherapy Treatment

eTable 1. Radiotherapy Treatment

	Overall	Conventional RT	SBRT
Total, n	195 ^a	128	63
RT dose, median (IQR), Gy	40.0 (36.0–50.4)	50.4 (36.0–50.4)	36.0 (36.0–40.0)
Number of fractions, median (IQR)	12.0 (5.0–28.0)	25.0 (12.0–28.0)	5.0 (3.0–5.0)
Concurrent chemotherapy, n (%)			
Capecitabine	90 (47.1)	90 (70.3)	0
Gemcitabine	23 (12.0)	23 (18.0)	0
Other	2 (1.0)	2 (1.6)	0
Unknown	6 (3.1) ^a	2 (2.3)	0
No concurrent chemotherapy	74 (37.9)	11 (8.6)	63 (100.0)

Missing data: type (n=4); dose (n=8); fractions (n=8); concurrent chemotherapy (n=4).

Abbreviations: IQR, interquartile range; RT, radiotherapy; SBRT, stereotactic body radiation therapy.

^aFor 4 patients, RT treatment specifics were unknown, therefore these could not be categorized.